ALBO   $44.175  0.54% Market Open

Albireo Pharma Inc
Last Events:

2023-03-29 Trend pattern changed from расширяющаяся формация to восходящий клин.

2023-03-29 Signal in Stochastic changed from bullish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-03-29 Signal in MACD changed from bullish to bearish reversal. Oscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: exit from the overbought zone.

2023-03-29 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: entrance to the overbought zone.

2023-03-29 Trend Power changed from to strong.

2023-03-29 Trend changed from down and flat to turning up.

2023-03-29 Trend pattern changed from восходящий клин to расширяющаяся формация.

2023-03-29 Signal in Stochastic changed from bearish weakening to bullish recovery. The stochastic indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: main and signal line crossing.


Current temperature: 1.01
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 29.31
Target: 44.00
High with 50% probability: 59.54
Analyst Recommendations:
Number of estimates 3
Target Price Mean 44.00
Mean unverified/preliminary 44.00 / 44.00
Target Price Low / High 42.00 / 48.00
Median / STD DEV 42.00 / 3.46
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell - Sell
rsi Sell Sell Sell
macd Sell - Sell
stoch Sell - -
ma20 - - -
ma50 - - -
ma100 - - -
Candlestick PatternFeb. 24, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US01345P1066
ceo Mr. Ronald H. W. Cooper
Website https://www.albireopharma.com
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..